UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

Nature communications, 2019-04, Vol.10 (1), p.1870-15, Article 1870

2019

Volltextzugriff (PDF)

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Nature communications, 2024-08, Vol.15 (1), p.7513-11, Article 7513

2024

Volltextzugriff (PDF)

Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment

PloS one, 2020-10, Vol.15 (10), p.e0240849-e0240849

2020

Volltextzugriff (PDF)

HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis

Nature communications, 2023-11, Vol.14 (1), p.7759-7759, Article 7759

2023

Volltextzugriff (PDF)

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (8), p.3041-3046

2008

Volltextzugriff (PDF)

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

PloS one, 2013-03, Vol.8 (3), p.e59588

2013

Volltextzugriff (PDF)

Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance

Molecular pharmaceutics, 2011-12, Vol.8 (6), p.2039-2049

2011

Volltextzugriff (PDF)

LIFE ISN'T FLAT: TAKING CANCER BIOLOGY TO THE NEXT DIMENSION

In vitro cellular & developmental biology. Animal, 2006-09, Vol.42 (8), p.242-247

2006

Volltextzugriff (PDF)

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells

Cancer research (Chicago, Ill.), 2007, Vol.67 (1), p.209-217

2007

Volltextzugriff (PDF)

Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice

Biomolecules (Basel, Switzerland), 2023-08, Vol.13 (9), p.1276

2023

Volltextzugriff (PDF)

Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles

Antioxidants, 2024-05, Vol.13 (5), p.555

2024

Volltextzugriff (PDF)

Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy

Journal of investigative dermatology, 2010-01, Vol.130 (1), p.28-37

Smalley, Keiran S.M.

2010

Volltextzugriff (PDF)

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.390-399

2013

Volltextzugriff (PDF)

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (7), p.2750-2760

2011

Volltextzugriff (PDF)

Drepmel—A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment

Cells (Basel, Switzerland), 2022-09, Vol.11 (18), p.2894

2022

Volltextzugriff (PDF)

Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia

Clinical cancer research, 2014-08, Vol.20 (16), p.4186-4192

2014

Volltextzugriff (PDF)

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

Biochemical pharmacology, 2011-08, Vol.82 (3), p.201-209

2011

Volltextzugriff (PDF)

A Mutational Survey of Acral Nevi

JAMA dermatology (Chicago, Ill.), 2021-07, Vol.157 (7), p.831

2021

Volltextzugriff (PDF)

Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells

Stem cells (Dayton, Ohio), 2006-07, Vol.24 (7), p.1668-1677

2006

Volltextzugriff (PDF)

Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

Expert opinion on pharmacotherapy, 2014-04, Vol.15 (5), p.589-592

2014

Volltextzugriff (PDF)

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

Clinical cancer research, 2012-05, Vol.18 (9), p.2502-2514

2012

Volltextzugriff (PDF)

GP100 expression is variable in intensity in melanoma

Cancer Immunology, Immunotherapy : CII, 2024-08, Vol.73 (10), p.191, Article 191

2024

Volltextzugriff (PDF)

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

Clinical cancer research, 2008-01, Vol.14 (1), p.230-239

2008

Volltextzugriff (PDF)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma

Cancer gene therapy, 2022-12, Vol.29 (12), p.1840-1846

2022

Volltextzugriff (PDF)

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

Clinical cancer research, 2017-10, Vol.23 (20), p.6203-6214

2017

Volltextzugriff (PDF)

1 – 25 von 214

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(198)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(214)
Japanisch
(33)

Erscheinungsjahr

n.n

Thema

Science & Technology
(167)
Life Sciences & Biomedicine
(152)
Humans
(147)
Oncology
(95)
Melanoma
(87)
Melanoma - Pathology
(60)
Melanoma - Drug Therapy
(59)
Animals
(52)
Melanoma - Genetics
(48)
Dermatology
(47)
Cell Line, Tumor
(46)
Melanoma - Metabolism
(42)
Proto-Oncogene Proteins B-Raf - Genetics
(40)
Mutation
(39)
Proto-Oncogene Proteins B-Raf - Antagonists & Inhibitors
(37)
Braf
(30)
Tumors
(30)
Mice
(29)
Biological And Medical Sciences
(26)
Cell Biology
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment

HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance

LIFE ISN'T FLAT: TAKING CANCER BIOLOGY TO THE NEXT DIMENSION

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells

Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice

Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles

Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

Drepmel—A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment

Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

A Mutational Survey of Acral Nevi

Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells

Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

GP100 expression is variable in intensity in melanoma

The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

Suchergebnisse filtern